Skip to Content

Dr Reddy's Laboratories Ltd ADR RDY

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Improving Outlook Supports Fair Value Estimate Increase for Dr. Reddy; Competition Prevents a Moat

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

We are raising our Dr. Reddy's fair value estimate to $49 after analyzing the positive trends impacting the firm. We now project high-single-digit revenue growth over our forecast period. The company has made a few acquisitions to replenish its portfolio over the past couple of years, including its 2020 acquisition of certain segments of Wockhardt’s generic business, consisting of roughly 62 brands across multiple therapies. These investments look to have a positive effect on the firm's growth potential. 

Read Full Analysis

Company Profile

Business Description

With headquarters in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceuticals. The firm operates in three divisions: global generics, pharmaceutical services and active ingredients, and proprietary products and other, which make up most of the company's revenue. Most of the company’s sales are based in the United States.

8-2-337, Road No. 3, Banjara Hills
Hyderabad, TG, 500 034, India
T +91 4049002900
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2021
Fiscal Year End Mar 31, 2022
Stock Type
Employees 22,739